KYSE770

Name: KYSE770
Brand: Creative Bioarray

Cat.No.: CSC-C6777J

Species: Homo sapiens (Human)

Source: Esophagus

Morphology: Epithelial-Like

Inquire for Price

Specification
Background
Scientific Data
Q & A
Customer Review

Cat.No.

CSC-C6777J

Description

Human moderately differentiated squamous cell carcinoma cell line established from esophageal cancer.

Species

Homo sapiens (Human)

Source

Esophagus

Recommended Medium

Ham's F12 medium and RPMI-1640 (1:1) + 2% FBS

Morphology

Epithelial-Like

Disease

Esophageal Squamous Cell Carcinoma

Storage

Liuqid Nitrogen, -180°C.

Shipping

Dry Ice.

Synonyms

KYSE-770; KYSE 770; KYSE0770

Citation Guidance

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

KYSE770, also designated KYSE-770, is an established human esophageal squamous cell carcinoma (ESCC) cell line derived from a moderately differentiated tumor in a 46-year-old male patient. The cells exhibit epithelial-like morphology and adherent growth. Their defined tissue origin and histological background provide a relevant experimental model for investigating esophageal squamous carcinoma biology and evaluating tumor-associated molecular targets.

A distinctive research advantage is their documented endogenous CD44 expression. This provides a practical basis for investigating antibody binding, epitope accessibility, and CD44-associated tumor phenotypes in a human cancer-cell context. KYSE770 also supports complementary assessment of antibody function in vitro and antitumor activity in vivo. A published study reported complement-dependent cytotoxicity against KYSE770 cells following treatment with two anti-CD44 antibodies and suppression of KYSE770 xenograft growth in mice. The antibodies differed in their ability to activate an FcγRIIIa-dependent reporter pathway in the presence of KYSE770 cells, illustrating the model’s value for distinguishing antigen recognition from downstream effector activity. These findings support comparative evaluation of antibody formats and mechanisms under defined experimental conditions.

Antitumor Activities of Anti‑CD44 Monoclonal Antibodies in Mouse Xenograft Models of Esophageal Cancer

Since CD44 plays a critical role in tumor development by regulating cell adhesion, survival, proliferation and stemness, it has been considered a target for tumor therapy. Anti‑CD44 monoclonal antibodies (mAbs) have been developed and applied to antibody‑drug conjugates and chimeric antigen receptor‑T cell therapy. Anti-pan‑CD44 mAbs, C₄₄Mab‑5 and C₄₄Mab‑46, which recognize both CD44 standard (CD44s) and variant isoforms were previously developed. The present study generated a mouse IgG_2a version of the anti‑pan‑CD44 mAbs (5‑mG_2a and C₄₄Mab‑46‑mG_2a) to evaluate the antitumor activities against CD44‑positive cells.

Both 5‑mG_2a and C₄₄Mab‑46‑mG_2a recognized CD44s‑overexpressed CHO‑K1 (CHO/CD44s) cells and esophageal tumor cell line (KYSE770) in flow cytometry. Furthermore, both 5‑mG_2a and C₄₄Mab‑46‑mG_2a could activate effector cells in the presence of CHO/CD44s cells and exhibited complement-dependent cytotoxicity (CDC) against both CHO/CD44s and KYSE770 cells. Furthermore, the administration of 5‑mG_2a and C₄₄Mab‑46‑mG_2a significantly suppressed CHO/CD44s and KYSE770 xenograft tumor development compared with the control mouse IgG_2a. These results indicate that 5‑mG_2a and C₄₄Mab‑46‑mG_2a could exert antitumor activities against CD44‑positive cancers and be a promising therapeutic regimen for tumors.